Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Peptide receptor radionuclide therapy for neuroendocrine tumours

    Peptide receptor radionuclide therapy for neuroendocrine tumours

    FromThe Lancet Oncology in conversation with

    Start listeningView podcast show

    Peptide receptor radionuclide therapy for neuroendocrine tumours

    FromThe Lancet Oncology in conversation with

    ratings:
    Length:
    20 minutes
    Released:
    Sep 5, 2020
    Format:
    Podcast episode

    Description

    Lisa Bodei (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses the Review in The Lancet Oncology on molecular profiling of neuroendocrine tumours to predict response to peptide receptor radionuclide therapy.Continue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
    Released:
    Sep 5, 2020
    Format:
    Podcast episode

    Titles in the series (100)

    Editors of The Lancet Oncology and the journal’s authors explore their research and its impact on people’s health, health care, and health policy in this regular podcast.